The RTX treatment was also effective in reducing the levels of a cytokine panel integrated by IL‐1β, IL‐6, IFN‐γ and TNF‐α on the lymphocyte population from SLE and RA patients (Figure 4B and 4). The gene discussed is IFNG; the disease is rheumatoid arthritis.